SGMO News and Press, Sangamo Therapeutics Inc. From 09/20/23

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City. Sandy Macrae, Sangamo’s President and Chief Executive Officer is...

2023-09-08 05:36:39 ET Summary Sangamo Therapeutics has faced challenges in recent years but has made moves and closed deals that have reignited interest in the company. The company has provided updates on its pipeline progress, including positive feedback from the FDA for its Fab...

2023-08-25 13:38:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it. And that in turn makes it more difficult for a company to develop and test eff...

2023-08-15 08:29:51 ET Delcath Systems ( DCTH ) +88% surges on FDA approval of cancer drug device. SCYNEXIS ( SCYX ) +24% Q2 earnings call release Grindr  ( GRND ) +23% FORM 10-Q | Quarterly Report. Taysha Gene Therapies ( TSHA ) +21% ....

2023-08-15 08:29:51 ET Delcath Systems ( DCTH ) +88% surges on FDA approval of cancer drug device. SCYNEXIS ( SCYX ) +24% Q2 earnings call release Grindr  ( GRND ) +23% FORM 10-Q | Quarterly Report. Taysha Gene Therapies ( TSHA ) +21% ....

2023-08-08 21:29:11 ET Sangamo Therapeutics, Inc. (SGMO) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Louise Wilkie – Vice President-Investor Relations and Corporate Communications Sandy Macrae – Chief Executive Office...

2023-08-08 16:15:54 ET Sangamo Therapeutics press release ( NASDAQ: SGMO ): Q2 GAAP EPS of -$0.66 misses by $0.32 . Revenue of $6.84M (-76.7% Y/Y) misses by $8.49M . The decrease of $22.5 million in revenues was primarily attributed to decreases of $8.5 million...

Conference call and webcast scheduled for Tuesday, August 8, 4:30 p.m. Eastern Time. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results. “I am extremely proud of our signi...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2023 financial results after the market closes on Tuesday, August 8, 2023. The press release will be followed by a conference call at 4:30 p....

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to...